Филтриране по Last updated date SelectСледПредиFrom - To Дата Крайна дата This week This month Last week Last month Category HumanCorporateVeterinaryHerbal Topic MedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceClinical trialsAdvanced therapiesData on medicinesCompliance and inspectionsInnovationResearch and developmentMedicine shortagesBiosimilarsSMEAntimicrobial resistanceGovernanceBrexitQuality of medicinesCorporateGeneric and hybrid medicinesEarly accessMedicines for use outside the EUFeesProduct informationScientific adviceMedical devicesMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate useCareersMedication errorParallel distributionPRIMEProcurement Diseases area Viral diseasesCancerImmune-system diseasesDiabetesNeurodegenerative diseasesCardiovascular diseasesHIV and AIDS Responsible body CHMP CVMP PRAC Management Board COMP PDCO CMDh HMPC CAT Patient safety Yes Leave this field blank Filter Резултати (3799) Sort by Last update date (new to old)Last update date (old to new)A-ZZ-A Leave this field blank IT systems intermittently unavailable from 16 to 18 April 2021 14 April 2021NewsCorporate Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 April 2021 9 April 2021NewsHumanCOVID-19PharmacovigilanceReferrals AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets 7 April 2021NewsHumanCOVID-19Vaccines AstraZeneca COVID-19 vaccine: review of very rare cases of unusual blood clots continues 31 March 2021NewsHumanCOVID-19Vaccines EU recommendations for 2021-2022 seasonal flu vaccine composition 30 March 2021NewsHumanMedicinesVaccines EMA working on COVID-19 over holiday period 30 March 2021NewsCorporateCOVID-19 Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna 26 March 2021NewsHumanCOVID-19Vaccines EMA issues advice on use of regdanvimab for treating COVID-19 26 March 2021NewsHumanCOVID-19Medicines Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021 26 March 2021NewsHumanCOVID-19Generic and hybrid medicinesMedicinesReferrals COVID-19 Vaccine AstraZeneca – Update on ongoing evaluation of blood clot cases 25 March 2021NewsHumanCOVID-19Vaccines 1 … 64 65 66 67 68 Page 68 of 380 69 70 71 72 … 380
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 April 2021 9 April 2021NewsHumanCOVID-19PharmacovigilanceReferrals
AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets 7 April 2021NewsHumanCOVID-19Vaccines
AstraZeneca COVID-19 vaccine: review of very rare cases of unusual blood clots continues 31 March 2021NewsHumanCOVID-19Vaccines
EU recommendations for 2021-2022 seasonal flu vaccine composition 30 March 2021NewsHumanMedicinesVaccines
Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna 26 March 2021NewsHumanCOVID-19Vaccines
EMA issues advice on use of regdanvimab for treating COVID-19 26 March 2021NewsHumanCOVID-19Medicines
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 March 2021 26 March 2021NewsHumanCOVID-19Generic and hybrid medicinesMedicinesReferrals
COVID-19 Vaccine AstraZeneca – Update on ongoing evaluation of blood clot cases 25 March 2021NewsHumanCOVID-19Vaccines